Anti-Inflammatory Drugs Market |2021 Analysis, Key Opportunities Major Players, Impact of COVID-19 and Size, Growth, Share, Regional Analysis With Global Industry Forecast To 2027, The global “Anti-Inflammatory Market” is expected to reach USD 191.42 billion by 2027 on account of increasing investments on the development of biologics for treating autoimmune inflammatory diseases. Anti-inflammatory drugs help to reduce inflammation in the body and treat health conditions such as arthritis, asthma, rheumatoid arthritis, sinusitis, and others. A recently published report by Fortune Business Insights offers a comprehensive overview of the market and its prime growth trajectories. As per the report titled, “Anti-Inflammatory Drugs Market Size, Share Industry Analysis, By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), By Application (Autoimmune Inflammatory Diseases (Rheumatoid Arthritis Psoriasis, and Others), Respiratory Diseases, and Others), By Route of Administration (Oral, Injection, Inhalation, and Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027,” the value of the market was USD 93.88 billion in 2019 and is expected to rise at a CAGR of 9.3% between 2020 to 2027.
Request a Sample Copy of the Research Report:
What are the Objectives of the Report?
The report offers a comprehensive overview of the market and its growth parameters such as drivers, restraints, challenges, and upcoming opportunities. The report also offers interesting insights into the market, current trends, and significant industry developments. It also throws light on key players functioning in the market and the key strategies adopted by them to compete for the top position. The report further discusses the segmentation of the market based on factors such as drug-class, application, route of administration, distribution channel, and geography, and lists the names of the leading segment with attributed factors. The report offers an overall qualitative and quantitative analysis of the market and is available for sale on the company website.
Antipsychotic Drugs Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market
Click here to get the short-term and long-term impact of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/anti-inflammatory-drugs-market-102825
Key Features of Anti-Inflammatory Drugs Market Report:
- Overview, Industry Life Cycle Analysis, Supply Chain Analysis
- Size, Trends, Growth Drivers, Constraints, SWOT Analysis, Forecast Analysis
- Competitive Landscapes: Market Share, Product Portfolio, New Product Launches, etc.
- Market attractiveness and Associated Growth Opportunities
- Strategic Growth Opportunities for the Existing and New Players
- Key Success Factors
Key Companies and Manufacturers Covered:
- Novartis AG
- AbbVie Inc.
- Biogen
- Merck Co., Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Johnson Johnson Services, Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Other Players
Market Drivers
Increasing Prevalence of Inflammatory Diseases will Add Impetus to Market
The increasing prevalence of inflammatory diseases namely ulcerative colitis, inflammatory bowel, psoriasis, and rheumatoid arthritis, and others are the major anti-inflammatory drugs market growth driver. As per the Centers for Disease Control and Prevention, an estimate of 78 million people in the U.S. will be diagnosed with arthritis by the end of 2040. Apart from this, the increasing uptake of corticosteroids for treating chronic obstructive pulmonary diseases (COPD) and asthma, coupled with the increasing prevalence of atopic dermatitis are likely to aid in the expansion of the market in the long run.
On the contrary, the side effects of using non-steroids anti-inflammatory drugs or NSAIDs such as dizziness, allergic reactions, stomach pain, stomach ulcers, and others may pose a major threat to the market in the coming years. This, coupled with the risk of gastrointestinal bleeding and other complications may hinder the market in the coming years.
